The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is ...

The firm will stop developing several of its own cell therapies to focus on advancing IMPT-314, a CAR T-cell therapy it is gaining by purchasing ImmPact.

The firm will use the funds to advance its pipeline of radiopharmaceutical agents, including an imaging agent currently being studied in melanoma.

The partners will use Pangea's ENLIGHT-DP platform to analyze data from two clinical studies at OHSU and improve understanding to tumor resistance and response.

PBGENE-HBV is designed to eliminate cccDNA and stop the hepatitis B virus from replicating, using the company's Arcus gene-editing platform.

Doctors are using limited guidance on screening and treatment approaches for transgender patients predisposed to cancer while considering patient preferences and treatment goals.

When doctors and other types of providers provide pretest genetic testing education to patients, it allows Clearview's ...

After meeting with the agency, the firm is optimistic it can submit a BLA for isaralgagene civaparvovec in the second half of 2025 using an intermediate endpoint.

Broad Institute and Northwestern University researchers are encouraging others to examine noncoding genes, when investigating ...

The combined company, which will be called Opus Genetics, will focus on advancing a pipeline of gene therapies for inherited retinal diseases.

Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.

The firm will use to funds to validate its CD123-targeted CAR T-cell therapies in acute myeloid leukemia in clinical studies.